INS and type 2 diabetes mellitus: The feasibility of innovative insulin delivery systems, which is viewed as a valid alternative to enable reduction of the number of injections [1], has been investigated in clinical studies, and more recently, the results of a phase 3a study revealed the superiority of a weekly insulin injection (insulin icodec) in decreasing HbA1c when compared with once daily insulin glargine in people with type 2 diabetes [2].